We found that among early stage, HR-positive, HER2-negative breast cancer patients, BRCA1/2 PV carriers receive more intensive, platinum-based chemotherapy regimens than other patients, for which there is neither evidence of benefit nor guideline recommendation (8). This evidence concerns the gene BRCA1 and breast cancer.